ToFAcitinib in Early Active Axial SpondyloarThritis:
Status:
Not yet recruiting
Trial end date:
2026-02-28
Target enrollment:
Participant gender:
Summary
This is a phase IV, multicentre, randomized, double-blind, placebo-controlled study designed
to compare the efficacy and safety of tofacitinib versus placebo (on a background of an
NSAID) over 16 weeks of treatment and 4 weeks of safety follow-up in subjects with early
active axSpA and inadequate response to at least one NSAID, with objective signs of
inflammation.